

# Bibliography

- AACAP. (2007), Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *Journal of the American Academy of Child and Adolescent Psychiatry*, 46 (11), 1503–1526.
- ACCME. (2017), Accreditation Council for Continuing Medical Education. Standards for Commercial Support.
- Adams, S.H. (1906), *The Great American Fraud*. New York: P.F. Collier & Son.
- Ahn, R., Woodbridge, A., Abraham, A., Saba, S., Korenstein, D., Madden, E., Boscardin, WJ., Keyhani, S. (2017), Financial ties of principal investigators and randomized controlled trial outcomes: Cross sectional study. *BMJ*, 356, i6770.
- Allgaier, A.K., Pietsch, K., Frühe, B., Sigl-Glöckner, J., Schulte-Körne, G. (2012), Screening for depression in adolescents: validity of the patient health questionnaire in pediatric care. *Depression and Anxiety*, (10), 906–913.
- Almasi, E.A., Stafford, R.S., Kravitz, R.L., Mansfield, P.R. (2006), What are the public health effects of direct-to-consumer drug advertising? *PLoS Medicine*, 3(3), e145.
- American Psychiatric Association, (2005), *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition. Washington DC: American Psychiatric Association.
- Amsterdam, J.D., McHenry L.B. (2012), The paroxetine 352 bipolar trial: A study in medical ghostwriting. *International Journal of Risk & Safety in Medicine*, 24(4), 221–231.
- Amsterdam, J.D., McHenry, L.B. (2019), The paroxetine 352 study revisited: Deconstruction of corporate and academic misconduct. *Journal of Scientific Practice and Integrity*, 1(1), 1–12.



- Amsterdam, J.D., McHenry, L.B., Jureidini, J. (2017), Industry-corrupted psychiatric trials. *Psychiatria Polska*, 51(6), 993–1008.
- Angell, M. (2000), Is academic medicine for sale? *The New England Journal of Medicine*, 342, 1516–1518.
- Angell, M. (2004), *The Truth About the Drug Companies: How They Deceive Us and What to Do About It*. New York: Random House.
- Angell, M. (2006), Your dangerous drugstore. *New York Review of Books*, 8 June, 38–40.
- Angell, M. (2008), Industry-sponsored clinical research: A broken system. *Journal of the American Medical Association*, 300(9), 1069–1071.
- Angell, M. (2009), Drug companies & doctors: a story of corruption. *New York Review of Books*. 15 January, 8–12.
- Avorn, J. (2004), *Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs*. New York: Alfred A. Knopf.
- Bachmann, C.J., Aagaard, L., Burcu, M., Glaeske, G., Kalverdijk, L., Petersen, I., Schuiling-Veninga, C.C., Wijlaars, L., Zito, J.M., Hoffmann, F. (2016), Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. *European Neuropsychopharmacology*. 26(3), 411–419.
- Barnes, E. (1947), *Social Institutions—In an Era of World Upheaval*. New York: Prentice-Hall.
- Bass, A. (2008), *Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial*. Chapel Hill: Algonquin.
- Baty, P. (2005), Data row sparks research debate. *The Times Higher Education Supplement*, 25 November, 9.
- Bekelman, J.E., Li, Y., Gross, C.P. (2003), Scope and impact of financial conflicts of interest in biomedical research: A systematic review. *Journal of the American Medical Association*, 289 (4), 454–456.
- Benbow A. (2004), Depressing misrepresentation? *Lancet* 363, 1732–1733.
- Bental, R. (2009), *Doctoring the Mind: Why Psychiatric Treatments Fail*. London: Penguin.
- Berenson, A. (2005), Evidence in Vioxx suits shows intervention by Merck officials. *New York Times*, 24 April, A–1.
- Bhatt, A. (2010), Evolution of clinical research: A history before and beyond James Lind. *Perspectives in Clinical Research*, 1/1, 6–10.
- Biederman, J. (2009), Video Deposition of Joseph Biederman, MD, in *Avilia vs. Johnson & Johnson Co, et al.* 26 February 2009. [www.industrydocuments.ucsf.edu/docs/#id=pjkgf0226](http://www.industrydocuments.ucsf.edu/docs/#id=pjkgf0226)
- Biegler, P. (2011), *The Ethical Treatment of Depression: Autonomy Through Psychotherapy*. Cambridge: MIT Press.



- Blind, E., Dunder, K., de Graeff, P.A., Abadie, E. (2011), Rosiglitazone: a European regulatory perspective. *Diabetologia*, 54, 213–218.
- Bloor, D. (1976), *Knowledge and Social Imagery*. Chicago: University of Chicago Press.
- Bok, D. (2003), *Universities in the Marketplace: The Commercialization of Higher Education*. Princeton: Princeton University Press.
- Bosch, X., Esfandiari, B., McHenry, L. (2012), Challenging medical ghostwriting in the U.S. courts. *PLoS Medicine*, 9(1), e1001163.
- Boylan, K., Romero, S., Birmaher, B. (2007), Psychopharmacologic treatment of pediatric major depressive disorder. *Psychopharmacology*, 191, 27–38.
- Braillon, A., Lexchin, J., Noble, J.H., Menkes, D., M'sahli, L., Fierlbeck, K., Blumsohn, A., Naudet, F. (2019), Challenging the promotion of antidepressants for nonsevere depression. *Acta Psychiatrica Scandinavica*, 1–2.
- Brennan, T.A., Rothman, D.J., Blank, L., Blumenthal, D., Chimonas, S.C., Cohen, J.J., Goldman, J., Kassirer, J.P., Kimball, H., Naughton, J., Smelser, N. (2006), Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. *Journal of the American Medical Association*, 295 (4), 429–433.
- Bridge, J.A., Iyengar, S., Salary, C.B., Barbe, R.P., Birmaher, B., Pincus, H.A., Ren, L., Brent, D.A. (2007), Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *Journal of the American Medical Association*, 297(15), 1683–1696.
- Brown, L. ed. (1993), *The New Shorter Oxford English Dictionary on Historical Principles*. Oxford: Clarendon Press.
- Burstow, B. (2015), *Psychiatry and the Business of Madness: An Ethical and Epistemological Accounting*. New York: Palgrave Macmillan.
- Carandang, C., Jabbar R., Macbride A., Elbe D. (2011), A review of escitalopram and citalopram in child and adolescent depression. *Journal of the Canadian Academy of Child and Adolescent Psychiatry*, 20(4), 315–324.
- Carlat, D. (2007), Dr. drug rep. *New York Times*. Nov. 25, 64–69.
- Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P.A., Favre, J., Simon, N., Bordet, R., Rolland, B. (2015), Off-label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends. *Current Pharmaceutical Design*, 21(23), 3280–3297.
- Carragee, E.J., Hurwitz, E.L., Weiner, B.K. (2011), A critical review of recombinant human bone morphogenetic protein-2 trials in spinal



- surgery: Emerging safety concerns and lessons learned. *The Spine Journal*, 11(6), 471–491.
- Cervero, R.M., He, J. (2008), The relationship between commercial support and bias in continuing medical education activities: A review of the literature. Chicago: Accreditation Council on Continuing Medical Education. [www.accme.org](http://www.accme.org)
- Chirac, P., Torreele, E. (2006), Global framework on essential health R&D. *Lancet*, 367, 1560–1561.
- Choudhry, N.K., Stelfox, H.T., Detsky, A.S. (2002), Relationships between authors of clinical practice guidelines and the pharmaceutical industry. *Journal of the American Medical Association*, 287, 612–617.
- Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S.E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., Cuijpers, P., Pu, J., Cohen, D., Ravindran, A.V., Liu, Y., Michael, K.D., Yang, L., Liu, L., Xie, P. (2016), Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet*, 388, 881–890.
- Cochrane, A.L. (1972), Effectiveness and efficiency: Random reflections on health services. Nuffield Provincial Hospitals Trust.
- Cohen, D. (2010), Rosiglitazone: What went wrong? *BMJ*, 341, c4848.
- Concato, J., Horwitz, R.I. (2019), Limited usefulness of meta-analysis for informing patient care. *Psychotherapy and Psychosomatics*, 88(5), 257–262.
- Cosgrove, L., Bursztajn, H.J., Krimsky, S., Anaya, M., Walker, J. (2009), Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines. *Psychotherapy and Psychosomatics*, 78(4), 228–232.
- Cosgrove, L., Bursztajn, H.J., Erlich, D.R., Wheeler, E.E., Shaughnessy, A.F. (2013), Conflicts of interest and the quality of recommendations in clinical guidelines. *Journal of Evaluation in Clinical Practice*, 19 (4), 674–681.
- Cosgrove, L., Krimsky, S. (2012), A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists. *PLoS Medicine*. 9(3), e1001190.
- Cosgrove, L., Krimsky, S., Wheeler, E.E., Kaitz, J., Greenspan, S.B., DiPentima, N.L. (2014), Tripartite conflicts of interest and high stakes patent extensions in the DSM-5. *Psychotherapy and Psychosomatics*, 83(2), 106–113.
- Cox, D.R., Donnelly, C.A. (2011), *Principles of Applied Statistics*. Cambridge: Cambridge University Press.



- Davies, J. (ed.) (2017), *The Sedated Society: The Causes and Harms of Our Psychiatric Drug Epidemic*. Palgrave Macmillan.
- De Vrieze, J. (2018), The metawars. *Science*, 361/6408, 1184–1188.
- Dimond, E.G., Kittle, C.F., Crockett, J.E. (1960), Comparison of internal mammary artery ligation and sham operation for angina pectoris. *American Journal of Cardiology*, 5(4), 483–486.
- Dijkers, M. (2013), Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development. KT Update, 1/5 [www.ktdrr.org/products/update/v1n5/](http://www.ktdrr.org/products/update/v1n5/)
- Dobrow, M.J., Hagens, V., Chafe, R., Sullivan, T., Rabeneck, L. (2018), Consolidated principles for screening based on a systematic review and consensus process. *Canadian Medical Association Journal*. 190(14), E422–E429.
- Donohue, J.M., Cevalco, M., Rosenthal, M.B. (2007), A decade of direct-to-consumer advertising of prescription drugs. *New England Journal of Medicine*, 357(7), 673–681.
- Doshi, P. (2013), EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. *BMJ*, 347, f5164.
- Doshi, P. (2015), No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. *BMJ*, 351, h4629.
- Doshi, P., Dickersin, K., Healy, D., Vedula, S., Jefferson, T. (2013), Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ*, 346, f2865.
- Dyer, C. (2010), Aubrey Blumsohn: Academic who took on industry. *BMJ*, 340, 22–23.
- Eddy, D.M. (1990), Practice policies: Where do they come from? *Journal of the American Medical Association*, 263(9), 1265–1275.
- Elliott, C. (2003), *Better than Well: American Medicine meets the American Dream*. New York: WW Norton.
- Elliott, C. (2004), Pharma goes to the laundry: Public relations and the business of medical education. *Hastings Center Report*, 34, 18–23.
- Elliott, C. (2008), Guinea-pigging. *New Yorker*. 7 January, 36–41.
- Elliott, C. (2010), *White Coat Black Hat: Adventures on the Dark Side of Medicine*. Boston: Beacon Press.
- Elliott, C. Abadie, R. (2008), Exploiting a research underclass in Phase 1 clinical trials. *New England Journal of Medicine*, 358 (22), 2316–2317.
- Emslie, G.J., Ventura, D., Korotzer, A., Tourkodimitris, S. (2009), Escitalopram in the Treatment of Adolescent Depression: A Randomized Placebo-Controlled Multisite Trial. *Journal of the American Academy of Child and Adolescent Psychiatry*, 48 (7), 721–729.



- Every-Palmer, S., Howick, J. (2014), How evidence-based medicine is failing due to biased trials and selective publication. *Journal of Evaluation in Clinical Practice*, 20, 908–914.
- Evidence Based Medicine Working Group (1992), Evidence based medicine: A new approach to teaching the practice of medicine. *Journal of the American Medical Association*, 258, 2420–2425.
- Fava G. (2002), Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. *Psychotherapy and Psychosomatics*, 71, 127–132.
- Fava G. (2004), Conflicts of interest in psychopharmacology: Can Dr Jekyll still control Mr Hyde? *Psychotherapy and Psychosomatics*, 73, 1–4.
- Fava G. (2006), A different medicine is possible. *Psychotherapy and Psychosomatics*, 75, 1–3.
- FDA. (2002a), Memo from Thomas P. Laughren, M.D. re Non-Approval Action for Pediatric Supplement for Celexa, 16 September 2002. [www.industrydocumentslibrary.ucsf.edu/drug/docs/zqmf0220](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/zqmf0220)
- FDA. (2002b), Clinical Review NDA: 20-031 Supplement S-037 Paroxetine HCI (Paxil) 4/11/02, Andrew D. Mosholder. [www.industrydocuments.ucsf.edu/docs/xsfw0217](http://www.industrydocuments.ucsf.edu/docs/xsfw0217)
- FDA. (2004), Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. [www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications](http://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications)
- FDA. (2007), FDA Science and Mission at Risk: Report of the Subcommittee on Science and Technology.
- FDA. (2018), Fact Sheet: FDA at a Glance. [www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance](http://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance)
- Feeley, J., Fisk, M. (2009), Glaxo Said to Have Paid \$1 Billion in Paxil Suits (Update2). *Bloomberg*, 14 December.
- Feynman, R. (1985), *Surely You're Joking, Mr Feynman!* New York: W.W. Norton.
- Flanagin A., Carey L.A., Fontanarosa, P.B., Phillips, S.G., Pace, B.P., Lundberg, G.D., Rennie, D. (1998), Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. *Journal of the American Medical Association*, 280 (3), 222–224.
- Forest (1999), Forest Research Institute. Study Protocol for MD-18. 1 September 1999. [industrydocuments.library.ucsf.edu/drug/docs/gpmf0220](http://industrydocuments.library.ucsf.edu/drug/docs/gpmf0220).
- Forest (2000a), E-mail re: FDA letter for CIT 18, 14–15 March 2000. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=kjbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=kjbn0225)



- Forest (2000b), Letter from Forest Laboratories to FDA Office of Drug Evaluation and Research. 20 March 2000. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=tjbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=tjbn0225)
- Forest (2000c), 2000 CNS/MSL Business Plan. 7 March 2000. [www.industrydocumentslibrary.ucsf.edu/drug/docs/jxbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/jxbn0225)
- Forest (2001a), E-mail re: Pediatric data, dated 10/15/01. [www.industrydocuments.library.ucsf.edu/drug/docs/pymf0220](http://www.industrydocuments.library.ucsf.edu/drug/docs/pymf0220)
- Forest (2001b) E-mail re: Pediatric data, dated 10/16/01. [industrydocuments.library.ucsf.edu/drug/docs/tymf0220](http://industrydocuments.library.ucsf.edu/drug/docs/tymf0220)
- Forest (2001c) E-mail re: Pediatric Manuscript, dated 12/17/01. [industrydocuments.library.ucsf.edu/drug/docs/yymf0220](http://industrydocuments.library.ucsf.edu/drug/docs/yymf0220)
- Forest (2001d), Email re: ACCAP meeting, dated 10/31/2001. [www.industrydocumentslibrary.ucsf.edu/drug/docs/kxbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/kxbn0225)
- Forest (2002a), Advertisement for CME Teleconference about Pediatric and Adolescent Depression. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=rjbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=rjbn0225)
- Forest (2002b), A Closer Look at Identifying Depression in Children and Adolescents—CME program. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=sjbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=sjbn0225)
- Forest (2002c), E-mail by Forest Staff re Peds Manuscript, dated 4/17/02. [industrydocuments.library.ucsf.edu/drug/docs/hymf0220](http://industrydocuments.library.ucsf.edu/drug/docs/hymf0220)
- Forest (2002d), Study Report for Protocol No. CIT-MD-18. 8 April 2002. [www.industrydocumentslibrary.ucsf.edu/drug/docs/fymf0220](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/fymf0220)
- Forest (2002e), Lexapro FY04. 12/20/2002. [www.industrydocuments.ucsf.edu/docs/#id=gjbn0225](http://www.industrydocuments.ucsf.edu/docs/#id=gjbn0225)
- Forest (2003), FY04 Lexapro Marketing Plan. [www.industrydocuments.ucsf.edu/docs/#id=jkww0217](http://www.industrydocuments.ucsf.edu/docs/#id=jkww0217)
- Forest (2004), Ghostwritten Wagner study published in *American Journal of Psychiatry*, dated 6/24/04. <http://industrydocuments.library.ucsf.edu/drug/docs/qkmf0220>
- Freedman, R., Roy, M.D. (2009), Editor's note. *American Journal of Psychiatry*, 166 (8), 942–943.
- Friedman, R.A. (2008). Review of Bass's *Side Effects*. *New England Journal of Medicine*, 358/26, 2854.
- Fugh-Berman, A. (2005), The corporate coauthor. *Journal of General Internal Medicine*, 20, 546–548.
- Fugh-Berman, A. (2010), The haunting of medical journals: How ghostwriting sold “HRT.” *PLoS Medicine*, 7(9), e1000335.
- Fugh-Berman, A., Batt S. (2006), This may sting a bit: Cutting CME's ties to pharma. *Virtual Mentor AMA Journal of Ethics*, 8 (6), 412–415.



- Fugh-Berman, A., Dodgson, S.J. (2008), Ethical considerations of publication planning in the pharmaceutical industry. *Open Medicine*, 2(4), e121–e124.
- Glassman P.A., Hunter-Hayes J., Nakamura T., (1999), Pharmaceutical advertising revenue and physicians organizations: How much is too much? *Western Journal of Medicine*, 171, 234–238.
- GlaxoSmithKline (2004), *BMJ*—manuscript decision. [www.industrydocumentslibrary.ucsf.edu/drug/docs/fxgw0217](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/fxgw0217)
- Glenmullen, J. (2005), *The Antidepressant Solution: A Step by Step Guide to Safety Overcoming Antidepressant Withdrawal, Dependence and 'Addiction'*. New York: The Free Press.
- Goldacre, B. (2012), *Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients*. London: Fourth Estate.
- Goldacre, B., Drysdale, H., Dale, A., Milosevic, I., Slade, E., Hartley, P., Marston, C., Powell-Smith, A., Heneghan, C., Mahtani, K.R. (2019), COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time. *Trials*. 20(1), 118.
- Golden G.A., Parochka J.N., Overstreet K.M. (2002), Medical education and communication companies: An updated in-depth profile. *Journal of Continuing Education in the Health Professions*, 22, 55–62.
- Gøtzsche, P. (2013), *Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare*. London: Radcliffe Publishing.
- Graham, D.J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., Ray, W.A., (2005), Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. *Lancet*, 365, 475–481.
- Grassley, C. (2010). Ghostwriting in medical literature. Minority Staff Report, 111th Congress, United States Senate Committee on Finance. Washington, DC.
- Greenberg, S.A. (2009), How citation distortions create unfounded authority: Analysis of a citation network. *BMJ*. 339, b2680.
- Greenhalgh, T., Howick, J., Maskrey, N. (2014), Evidence based medicine: A movement in crisis? *BMJ*, 348, g3725.
- Greenslit, N.P., Kaptchuk, T.J. (2012), Antidepressants and advertising: Psychopharmaceuticals in crisis. *Yale Journal of Biology and Medicine*, 85(1), 153–158.
- Guyatt, G. (1991), Evidence-based medicine. *American College of Physicians Journal Club*, 114, A16.



- Hammad, T.A., Laughren, T.P., Racoosin, J.A. (2006), Suicide rates in short-term randomized controlled trials of newer antidepressants. *Journal of Clinical Psychopharmacology*. 26(2), 203–207.
- Handel, A.E., Patel, S.V., Pakpoor, J., Ebers, G.C., Goldacre, B., Ramagopalan, S.V. (2012). High reprint orders in medical journals and pharmaceutical industry funding: Case-control study. *BMJ*, 344, e4212.
- Harmer, C.J., Shelley, N.C., Cowen, P.J., Goodwin, G.M. (2004), Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. *American Journal of Psychiatry*. 161(7), 1256–1263.
- Harris, G. (2004), Expert kept from speaking at antidepressant hearing. *New York Times*, 16 April.
- Harris, G. (2008), Top psychiatrists didn't report drug makers' pay. *New York Times*, 3 October.
- Hart, P.D. (1999), A Change in scientific approach: From alternation to randomized allocation in clinical trials in the 1940s. *BMJ*. 319, 572–573.
- Hartung, D.M., Zarin, D.A., Guise, J.M., McDonagh, M., Paynter, R., Helfand, M. (2014), Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. *Annals of Internal Medicine*, 160(7), 477–483.
- Harvard Medical School. (2016), Harvard University Faculty of Medicine Policy on Conflicts of Interest and Commitment.
- Hayek, F. ([1944] 1994), *The Road to Serfdom*. Chicago: University of Chicago Press.
- Healy, D. (1987), The structure of psychopharmacological revolutions. *Psychiatric Developments*, 4, 349–376.
- Healy, D. (1997), *The Antidepressant Era*. Cambridge: Harvard University Press.
- Healy, D. (1996, 2000a), *The Psychopharmacologists*. Vols 1, 3. London: Altman.
- Healy, D. (2000b), Good science or good business. *Hastings Center Report*, 30, 19–22.
- Healy, D. (2002), Conflicting interests in Toronto: Anatomy of a controversy at the interface of academia and industry. *Perspectives in Biology and Medicine*, 45(2), 250–263.
- Healy D. (2004), *Let Them Eat Prozac*. New York: New York University Press.
- Healy, D. (2006), Hasty bolt down the aisle or a well-considered union? *The Times Higher Educational Supplement*, 18 August.
- Healy D. (2007), Pediatric bipolar disorder: An object of study in the creation of an illness. *International Journal of Risk & Safety in Medicine*, 19, 209–221.



- Healy, D. (2008), Our censored journals. *Mens Sana Monographs*, 6, 282–294.
- Healy, D. (2012), *Pharmageddon*. Berkeley: University of California Press.
- Healy, D., Langmack, C., Savage M. (1999), Suicide in the course of treatment of depression. *Journal of Psychopharmacology*, 13/1: 94–99.
- Healy, D., Cattell, D. (2003), Interface between authorship, industry and science in the domain of therapeutics, *British Journal of Psychiatry*, 183, 22–27.
- Healy, D., Thase, M. (2003), Is academic psychiatry for sale? *British Journal of Psychiatry*, 182, 1–3.
- Healy, D., LeNoury, J., Jureidini, J.N. (2018), Paediatric antidepressants: Benefits and risks. *International Journal of Risk & Safety in Medicine*, 30, 1–7.
- Henderson, S.W., Horwitz, A.V., Wakefield, J.C. (2009), Should screening for depression among children and adolescents be demedicalized? *Journal of the American Academy of Child and Adolescent Psychiatry*, 48(7), 683–687.
- Heydorn, W. (2007), Videotaped deposition of William E. Heydorn, PhD, in Celexa and Lexapro Marketing and Sales Practices Litigation. [www.industrydocumentslibrary.ucsf.edu/drug/docs/hlbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/hlbn0225)
- Hengartner, M.P. (2017), Methodological flaws, conflicts of interest, and scientific fallacies: Implications for the evaluation of antidepressants' efficacy and harm. *Frontiers in Psychiatry*, 8, 275.
- Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., Leucht, S. (2006), Why Olanzapine beats Risperidone, Risperidone beats Quetiapine, and Quetiapine beats Olanzapine: An explanatory analysis of head-to-head comparison studies of second-generation antipsychotics. *American Journal of Psychiatry*, 163, 185–194.
- Hill, M. (2009), Ghosts in the Medical Machine. *Philadelphia Inquirer*, 20 September.
- Holmes, O.W., Sr. (1860), *Collected Works: Currents and Counter-Currents in Medical Science*. In *American Journal of the Medical Sciences*, 40, 467.
- Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., Nomajda, M., McMurray, J.J., RECORD Study Team. (2009), Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. *Lancet*, 373, 2125–2135.
- Horton, R. (2004a), The dawn of McScience, *New York Review of Books*, 11 March, 7–9.
- Horton, R. (2004b), Depressing research. *Lancet*, 363, 1335.
- House of Commons Health Committee. (2005), The influence of the pharmaceutical industry, Vol. 1. London: The Stationery Office.



- Howick, J. (2011), *The Philosophy of Evidence-Based Medicine*. Oxford: Wiley-Blackwell.
- Hughes, C.W., Emslie, G.J., Crismon, M.J., Wagner, K.D., Birmaher, B., Geller, B., Pliszka, S.R., Ryan, N.D., Strober, M., Trivedi, M.H., Toprac, M.G., Sedillo, A., Llana, M.E., Lopez, M., Rush, A.J. (1999), The Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. The Texas Children's Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 38 (11), 1442–1454
- IntraMed (2008a), Lexapro Adolescent Key Opinion Leaders (KOL) Mapping Proposal. [www.industrydocuments.ucsf.edu/docs/rhbn0225](http://www.industrydocuments.ucsf.edu/docs/rhbn0225)
- IntraMed (2008b), List Rental Order—Psychiatry Survey. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=phbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=phbn0225)
- IntraMed (2008c), Criteria Used to Develop Influence Score. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=shbn0225](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=shbn0225)
- Ioannidis, J. (2017), Outcome reporting bias in clinical trials: why monitoring matters. *BMJ*, 356, j408.
- JAACAP. (2000), Instructions for authors. [www.healthyskepticism.org/files/news\\_int/2010/JAACAP\\_author\\_instructions\\_2000.pdf](http://www.healthyskepticism.org/files/news_int/2010/JAACAP_author_instructions_2000.pdf)
- Jacobs, A., Wager, E. (2005), European medical writers association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. *Current Medical Research and Opinion*, 21(2), 317–321.
- Jefferson, T., Jørgensen, L. (2018), Redefining the 'E' in EBM. *BMJ Evidence-Based Medicine*, 23/2, 46–47.
- Jeffrey, B., Vinay, P. (2016), Future jobs of FDA's haematology-oncology reviewers. *BMJ*, 354, i5055.
- Jofre, S. (2007), British Broadcasting Company (BBC), *Panorama*, "Secrets of the Drug Trials," 01/29/2007. [news.bbc.co.uk/1/hi/programmes/panorama/6317137.stm](http://news.bbc.co.uk/1/hi/programmes/panorama/6317137.stm)
- Jørgensen, L., Gøtzsche, P., Jefferson, T. (2018), The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias, *BMJ Evidence-Based Medicine*, 23/5, 165–168.
- Jureidini, J. (2007), The black box warning: Decreased prescriptions and increased youth suicide? *American Journal of Psychiatry*, 164(12), 1907.
- Jureidini, J. (2012), Key opinion leaders in psychiatry: A conflicted pathway to career advancement. *Australian & New Zealand Journal of Psychiatry*, 46, 495–497.
- Jureidini, J.N., Tonkin, A. (2003), Paroxetine in major depression. *Journal of the American Academy of Child and Adolescent Psychiatry*, 42, 514.



- Jureidini, J., Mansfield, P. (2006), The scope of the problem of the relationship between drug companies and doctors. *Critical Voices in Child and Adolescent Mental Health*. Edited by S. Timimi, B. Maitra. London: Free Association, 29–39.
- Jureidini, J.N., McHenry, L.B., Mansfield, P.R. (2008), Clinical trials and drug promotion: Selective reporting of Study 329, *International Journal of Risk & Safety in Medicine*, 20, 73–81.
- Jureidini, J., McHenry, L. (2009), Key opinion leaders and paediatric antidepressant overprescribing. *Psychotherapy and Psychosomatics*, 78, 197–201.
- Jureidini, J.N., McHenry, L.B. (2011), Conflicted medical journals and the failure of trust. *Accountability in Research*, 18, 45–54.
- Jureidini, J., Nardo, J.M. (2014), Inadequacy of remote desktop interface for independent reanalysis of data from drug trials. *BMJ*, 349, g4353.
- Jureidini, J.N., Amsterdam, J.D., McHenry, L.B. (2016), The Citalopram CIT-MD-18 pediatric depression trial: A deconstruction of medical ghostwriting, data manipulation and academic malfeasance. *International Journal of Risk & Safety in Medicine*, 28, 33–43.
- Kallet, A., Schlink, F.J. (1933), *100 Million Guinea Pigs: Dangers in Everyday Foods, Drugs and Cosmetics*. New York: Vanguard Press.
- Karanges, E.A., Ting, N., Parker, L., Fabbri, A., Bero, L. (2020), Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. *Australian Journal of General Practice*, 49, 151–154.
- Kassirer, J.P. (2005), *On the Take: How America's Complicity with Big Business Can Endanger Your Health*. New York: Oxford University Press.
- Keller, M.B., Ryan, N.D., Strober, M., Klein, R.G., Kutcher, S.P., Birmaher, B., Hagino, O.R., Koplewicz, H., Carlson, G.A., Clarke, G.N., Emslie, G.J., Feinberg, D., Geller, G., Kusumakar, V., Papatheodorou, G., Sack, W.H., Sweeney, M., Wagner, K.D., Weller, E.B., Winters, N.C., Oakes, R., McCafferty, J.P. (2001), Efficacy of Paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *Journal of the American Academy of Child and Adolescent Psychiatry*, 40, 762–772.
- Kesselheim, A.S., Avorn, J. (2007), The role of litigation in defining drug risks. *Journal of the American Medical Association*, 297(3), 308–331.
- Kirk, S., Gomory, T., Cohen, D. (2013). *Mad Science: Psychiatric Coercion, Diagnosis, and Drugs*. Piscataway, NJ: Transaction Publishers.
- Kirsch, I., Moore, T.J., Scoboria, A., Nicholls, S.S. (2002), The emperor's new drugs: An analysis of antidepressant medication data submitted to the US Food and Drug Administration. *Prevention & Treatment* 5/23.



- Krimsky, S. ([2003] 2004), *Science in the Private Interest*. Lanham: Roman & Littlefield.
- Krimsky, S. (2006a), Autonomy, disinterest, and entrepreneurial science. *Society*, 43/4, 22–29.
- Krimsky S. (2006b), Publication bias, data ownership, and the funding effect in science: Threats to the integrity of biomedical research. *Rescuing Science from Politics: Regulation and Distortion of Scientific Research*. Edited by W. Wagner and R. Steinzor. Cambridge: Cambridge University Press, 61–85.
- Kroenke, K., Spitzer, R.L., Williams, J.B. (2001), The PHQ-9: validity of a brief depression severity measure. *Journal of General Internal Medicine*. 16(9), 606–613.
- Kuhn, T. (1962), *The Structure of Scientific Revolutions*. Chicago: The University of Chicago.
- Lacasse, J.R., Leo, J. (2005) Serotonin and depression: A disconnect between the advertisements and the scientific literature. *PLoS Medicine*, 2(12), e392.
- Lacasse, J.R., Leo, J. (2010), Ghostwriting at elite academic medical centers in the United States. *PLoS Medicine*, 7(2), e1000230.
- LaPorta, L. (1993), Sertraline-induced akathisia. *Journal of Clinical Psychopharmacology*, 13/3, 219–220.
- Lane, C. (2007), *Shyness: How Normal Behavior Became a Sickness*. New Haven: Yale University Press.
- Larsen, D. (2009), Pot-smoking Phelps isn't alone among athletes. *Forbes*, 4 February.
- Larkin, M. (1999), Whose article is it anyway? *Lancet*, 354, 136.
- Latour, B., Woolgar, S. (1986), *Laboratory Life: The Construction of Scientific Facts*, Princeton: Princeton University Press.
- Law, J. (2006), *Big Pharma: Exposing the Global Healthcare Agenda*, New York: Carroll and Graf Publishers.
- Lawrence, D., Hancock, K.J., Kiseley, S. (2013), The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. *BMJ*, 346, f2539.
- Leddy, C. (2008), The unhealthy ties that bind FDA to drug firms. *Boston Globe*. 5 July.
- Lederberg, J. (1993), Communication as the root of scientific progress. *Scientist*. 7 (3), 10–14.
- Le Noury, J., Nardo, J.M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., Abi-Jaoude, E. (2015), Restoring Study 329: efficacy and harms



- of paroxetine and imipramine in treatment of major depression in adolescence. *BMJ*, 351, h4320.
- Lenzer, J. (2012), Controversial mental health program closes down. *BMJ*, 2345, e8100.
- Letiecq, B. (2019), George Mason University's donor problem and the fight for transparency. *Academe*. 105 (2), 22–26.
- Levin, A. (2016), Child psychiatrists look at specialty from both macro, micro perspectives. *Psychiatric News*. 51(12), 23–37.
- Levin, E.C., Parry, P.I. (2011), Conflict of interest as a possible factor in the rise of pediatric bipolar disorder. *Adolescent Psychiatry*. 1, 61–66.
- Lexchin, J. (2012), Sponsorship bias in clinical research. *International Journal of Risk & Safety in Medicine*. 24:233–242.
- Lexchin, J., Light, D.W. (2006), Commercial influence and the content of medical journals, *BMJ*, 332, 1444–1447.
- Light, D.W. (ed.) (2010), *The Risks of Prescription Drugs*. New York: Columbia University Press.
- Lind, J. (1753), *A Treatise of the Scurvy in Three Parts*. Edinburgh: Sands, Murray and Cochran.
- Lisse, J.R., Perlman, M., Johansson, G., Shoemaker, J.R., Schechtman, J., Skalky, C.S., Dixon, M.E., Polis, A.B., Mollen, A.J., Geba, G.P. (2003), Gastrointestinal tolerability and effectiveness of Rofecoxib versus naproxen in the treatment of osteoarthritis, *Annals of Internal Medicine*, 139, 539–546.
- Locher, C., Koechlin, H., Zion, S.R., Werner, C., Pine, D.S., Kirsch, I., Kessler, R.C., Kossowsky, J. (2017), Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: A systematic review and meta-analysis, *JAMA Psychiatry*, 74(10), 1011–1020.
- Logdberg, L. (2011), Being a ghost in the machine: A medical ghostwriter's personal view. *PLoS Medicine*, 8(8), e1001071.
- Mansi, B.A., Clark, J., David, F.S., Gessell, T.M., Glasser, S., Gonzalez, J., Haller, D.G., Laine, C., Miller, C.L., Mooney, L.A., Zecevic, M. (2012), Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: A joint journal and pharmaceutical industry perspective. *Mayo Clinic Proceedings*, 87(5), 424–429.
- Marks, H.M. (1997), *The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990*. Cambridge: Cambridge University Press.
- Martin, A. (2010), Letter to Jureidini, 2 July 2010. [www.healthyskepticism.org/files/news\\_int/2010/Rejection%20from%20Martin%20Jul02.pdf](http://www.healthyskepticism.org/files/news_int/2010/Rejection%20from%20Martin%20Jul02.pdf)



- Martin, A., Gilliam, W.S., Bostic, J.Q., Rey, J.M. (2005), Letter to the editor. Child psychopharmacology, effect sizes, and the big bang. *American Journal of Psychiatry*, 162 (4), 817.
- Martin, A., Faraone, S.V., Henderson, S.W., Hudziak, J.J., Leibenluft, E., Piacentini, J., Bradley, S., Todd, R.D., Walkup, J. (2008), Conflict of interest. *Journal of the American Academy of Child and Adolescent Psychiatry*. 47(2), 119–120.
- Masand, P., Gupata, S., Dewan, M. (1991), Suicidal ideation related to fluoxetine treatment. *New England Journal of Medicine*. 324/6, 420.
- Matheson, A. (2011), How industry uses the ICMJE guidelines to manipulate authorship—And how they should be revised. *PLoS Medicine*, 8, e1001072.
- Mathews, M., Adetunji, B., Mathews, J., Basil, B., George, V., Mathews, M., Budur, K., Abraham, S. (2005), Child psychopharmacology, effect sizes, and the big bang. *American Journal of Psychiatry*, 162 (4), 818.
- Maxwell, N. (1984), *From Knowledge to Wisdom: A Revolution for Science and the Humanities*. Oxford: Basil Blackwell.
- Maxwell, N. (2014), *Global Philosophy: What Philosophy Ought to Be*. Exeter: Imprint Academic.
- Mayo, D. (2018), *Statistical Inference as Severe Testing: How to Get Beyond the Statistics Wars*. Cambridge: Cambridge University Press.
- Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J.K., Dickersin, K., MUDs Investigators. (2019a), Harms are assessed inconsistently and reported inadequately Part 1: systematic adverse events. *Journal of Clinical Epidemiology*, 113, 20–27.
- Mayo-Wilson, E., Fusco, N., Li T., Hong, H., Canner, J.K., Dickersin, K., MUDs Investigators (2019b), Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. *Journal of Clinical Epidemiology*, 113, 11–19.
- McCafferty, J. (2006), Deposition of James McCafferty, 24–26 August, [www.healthyskepticism.org/documents/documents/McCaffertyDeposition.pdf](http://www.healthyskepticism.org/documents/documents/McCaffertyDeposition.pdf)
- McGarity, T.O., Wagner, W.E. (2008), *Bending Science: How Special Interests Corrupt Public Health Research*, Cambridge: Harvard University Press.
- McHenry, L. (2005), On the origin of great ideas: Science in the age of big pharma. *Hastings Center Report*, 35, 17–19.
- McHenry, L. (2007), Commercial influences on the pursuit of wisdom. *London Review of Education*, 5, 131–142.
- McHenry, L. (2008), Biomedical research and corporate interests: A question of academic freedom. *Mens Sana Monographs*, 6, 171–182.



- McHenry, L. (2010), Of sophists and spin-doctors: Industry-sponsored ghostwriting and the crisis of academic medicine. *Mens Sana Monographs*, 8, 129–145.
- McHenry, L. (2018), The Monsanto papers: Poisoning the scientific well. *International Journal of Risk & Safety in Medicine*, 29 (3–4), 193–205.
- McHenry, L., Jureidini, J. (2008), Industry-sponsored ghostwriting in clinical trial reporting: A case study. *Accountability in Research*, 15, 152–167.
- McHenry, L., Jureidini, J. (2009), Privatization of knowledge and the creation of biomedical conflicts of interest. *Journal of Ethics in Mental Health*, 4 (1), 1–6.
- McHenry, L., Jureidini, J. (2012a), On the proposed changes to the credibility gap in industry-supported biomedical research: A critical evaluation. *Ethical Human Psychology & Psychiatry*, 14 (3), 156–161.
- McHenry, L., Jureidini, J. (2012b), Any Reasonable Person' Would See Glaxo Study as Fraud. *The Chronical of Higher Education*, 12 October.
- McHenry, L., Khoshnood, M. (2014), Blood money: Bayer's inventory of HIV-contaminated blood products and third world haemophiliacs. *Accountability in Research*, 21, 389–400.
- Medicines and Healthcare Products Regulatory Agency (2008), MHRA Investigation into GlaxoSmithKline/Seroxat, 6 March 2008. webarchive. nationalarchives.gov.uk/20141206221413/www.mhra.gov.uk/home/groups/es-policy/documents/websiteresources/con014155.pdf
- Meldrum, M.L. (2000), A brief history of the randomized controlled trial: From oranges and lemons to the gold standard. *Hematology/Oncology Clinics of North America*, 14 (4), 745–760.
- Mintzes, B., Mangin, D. (2009), Direct-to-consumer advertising of prescription medicines: A counter argument. *Future Medicinal Chemistry*, 1 (9), 1555–1560.
- Moffatt, B., Elliott, C. (2007), Ghost marketing: Pharmaceutical companies and ghostwritten journal articles. *Perspectives in Biology and Medicine*, 50 (1), 18–31.
- Moreno, C., Roche, A.M., Greenhill, L.L. (2006), Pharmacotherapy of child and adolescent depression. *Journal of Child and Adolescent Psychiatric Clinics of North America*, 15, 977–998.
- Moynihan, R. (2008a), Key opinion leaders: Independent experts or drug representatives in disguise? *BMJ*, 336, 1402–1403.
- Moynihan, R. (2008b), Is the relationship between pharma and medical education on the rocks? *BMJ*, 337, a925.
- Moynihan, R., Cassels, A. (2005), *Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All into Patients*. New York: Nation Books.



- Moynihan, R., Henry, D. (2006), The fight against disease mongering: Generating knowledge for action. *PLoS Medicine*, 3(4), e191.
- Mundy, A. (2001), *Dispensing with the Truth: The Victims, the Drug Companies, and the Dramatic Story Behind the Battle over Fen-Phen*. New York: St. Martin's Press.
- Nemeroff, C.B., (ed.) (2003), Advancing the treatment of mood and anxiety disorders: The first 10 years' experience with paroxetine. *Psychopharmacology Bulletin*, 37, 6–177.
- Newman, M. (2010), The rules of retraction. *BMJ*, 341, 1246–1248.
- Newman, M. (2019), Has Cochrane lost its way? *BMJ*, 364, k5302.
- New York State Office of the Attorney General (2004). Settlement sets new standard for release of drug information. [ag.ny.gov/press-release/2004/settlement-sets-new-standard-release-drug-information](http://ag.ny.gov/press-release/2004/settlement-sets-new-standard-release-drug-information)
- Nulsen, R.O. (1961), Trial of thalidomide in insomnia associated with the third trimester. *American Journal of Obstetrics and Gynecology*, June, 1245–1248.
- Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D., Fleming, K.A. (1998). Long-term safety and effectiveness of iron chelation therapy with oral deferiprone in patients with thalassemia major. *New England Journal of Medicine*. 339 (7), 417–428.
- Outterson, K. (2012), Punishing health care fraud—Is the GSK settlement sufficient? *New England Journal of Medicine*. 367, 1082–1085.
- Ozierski, P., Csanadi, M., Rickard, E., Tchilingirian, J., Mulinari, S. (2019), Analysis of pharmaceutical industry payments to UK health care organizations in 2015. *JAMA Network Open*. 2(6), e196253.
- Parsons (2002), Paroxetine in Adolescent Major Depression. *Journal of the American Academy of Child and Adolescent Psychiatry*. 41(4), 364.
- Pharmaceutical Research and Manufacturers of America. (2015), Principles on Conduct of Clinical Trials, Communication of Clinical Trial Results. [docplayer.net/3195409-Conduct-of-clinical-trials-communication-of.html](http://docplayer.net/3195409-Conduct-of-clinical-trials-communication-of.html)
- PLoS Medicine Editors. (2006), *PLoS Medicine* and the pharmaceutical industry. *PLoS Medicine*. 3(7), e329.
- Pollack, A. (2012), Questcor finds profits, at \$28,000 a vial. *New York Times*, 29 December.
- Pollock, B.G. (1998), Discontinuation symptoms and SSRIs, *Journal of Clinical Psychiatry*. 59(10), 535–536.
- Popper, K. ([1945] 1950), *The Open Society and its Enemies*. 2 vols. London: Routledge.



- Popper, K. ([1934] 1959), *The Logic of Scientific Discovery*. New York: Basic Books.
- Popper, K. ([1957] 1961), *The Poverty of Historicism*. New York: Harper Torchbooks.
- Popper, K. ([1962] 1968), *Conjectures and Refutations: The Growth of Scientific Knowledge*. London: Routledge.
- Popper, K. (1972), *Objective Knowledge: An Evolutionary Approach*. Oxford: Clarendon Press.
- Popper, K. (1994), *The Myth of the Framework: In Defence of Science and Rationality*. Edited by M.A. Notturmo. London: Routledge.
- Porter, J., Jick, H. (1980), Addiction rare in patients treated with narcotics. *New England Journal of Medicine*, 302, 123.
- Prescrire, (2018), Towards better patient care: drugs to avoid in 2018. *Prescrire International*, 27, 107–111.
- Rees, S.T. (2003), Who actually wrote the research paper? How to find out. *BMJ Rapid Responses*. *BMJ*, 326, 1202.
- Rennie, D., Yank, V., Emanuel, L. (1997), When authorship fails: A proposal to make contributors accountable. *Journal of the American Medical Association*, 278(7), 579–585.
- Resnik, D.B., Shamoo, A.E. (2002), Conflict of interest and the university. *Accountability in Research*, 91, 45–62.
- Resnik, D.B., Ariansen, J.L., Jamal, J., Kissling, G.E. (2016), Institutional conflict of interest policies at U.S. academic research institutions. *Academic Medicine*. 912, 242–246.
- Rising, K., Bacchetti, P., Bero, L. (2008), Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. *PLoS Medicine*, 5(11), e217.
- R.J. Reynolds (1985), A. Wallace Hayes, Reynolds Tobacco Company Inter-Office Memorandum, 8 January 1985, [www.industrydocumentslibrary.ucsf.edu/docs/ykfw0079](http://www.industrydocumentslibrary.ucsf.edu/docs/ykfw0079)
- Rosack, J. (2004), FDA issues controversial black box warning. *Psychiatric News*. 5 November.
- Roseman, M., Kloda, L.A., Saadat, N., Riehm, K.E., Ickowicz, A., Baltzer, F., Katz, L.Y., Patten, S.B., Rousseau, C., Thombs, B.D. (2016). Accuracy of depression screening tools to detect major depression in children and adolescents: A systematic review. *Canadian Journal of Psychiatry*, 61(12), 746–757.
- Rosenbaum, J.F., Zajecka, J. (1997), Clinical management of antidepressant discontinuation. *Journal of Clinical Psychiatry*, 58, Supplement 7, 37–40.
- Rosenberg, M. (2012), Former FDA reviewer speaks out about intimidation, retaliation and marginalizing of safety. *Truthout*, 29 July.



- Ross, J.S., Hill, K.P., Egilman, D.S., Krumholz, H.M. (2008), Guest authorship and ghostwriting in publications related to Rofecoxib: A case study of industry documents from Rofecoxib litigation. *Journal of the American Medical Association*, 299, 1800–1812.
- Ross, J.S. Gross, C.P., Krumholz, H.M. (2012), Promoting transparency in pharmaceutical industry-sponsored research. *American Journal of Public Health*, 102, 72–80.
- Ruane, T.J. (2000), Letter to the editor, Is academic medicine for sale? *New England Journal of Medicine*, 343, 509.
- Sackett, D.L. (1997), Evidence-based medicine. *Seminars in Perinatology*, 21, 3–5.
- Sackett, D.L., Rosenberg, J.A.M., Gray, W.M.C., Haynes, R.B., Richardson, W.S. (1996), Evidence Based Medicine: What it is and what it isn't. *BMJ*, 312, 71–72.
- Schafer, A. (2004), Biomedical conflicts of interest: A defense of the sequestration thesis—Learning from the cases of Nancy Olivieri and David Healy. *Journal of Medical Ethics*, 30, 8–24.
- Schafer, A. (2007), Commentary: Science scandal or ethics scandal? Olivieri redux. *Bioethics*, 21 (2), 111–115.
- Schott, G., Dünnweber, C., Mühlbauer, B., Niebling, W., Pacht, H., Ludwig, W.D. (2013), Does the pharmaceutical industry influence guidelines?: Two examples from Germany. *Deutsches Ärzteblatt International*, 110(35–36), 575–583.
- Scientific Therapeutics Information (2000), Email from Sally Laden to Daniel Burnham re: Par 222 manuscript, 14 December 2000. [www.industrydocuments.ucsf.edu/docs/snxl0228](http://www.industrydocuments.ucsf.edu/docs/snxl0228)
- Scientific Therapeutics Information (2005), Paxil-Funded Publications 1998 to Current. [www.industrydocuments.ucsf.edu/docs/znxl0228](http://www.industrydocuments.ucsf.edu/docs/znxl0228)
- Scientific Therapeutics Information (2006), Scientific Therapeutics Information, Inc. website. [web.archive.org/web/20040405204110/stimedinfo.com](http://web.archive.org/web/20040405204110/stimedinfo.com)
- Senate Finance (2008), Exhibit A: Speaker Event and Professional Programs Databases. [www.industrydocuments.ucsf.edu/docs/hgfw0217](http://www.industrydocuments.ucsf.edu/docs/hgfw0217)
- Senate Finance (2012), Staff report on Medtronic's influence on InFuse clinical studies, October. [www.finance.senate.gov/chairmans-news/baum-grassley-investigation-into-medtronic-reveals-manipulated-studies-close-financial-ties-with-researchers](http://www.finance.senate.gov/chairmans-news/baum-grassley-investigation-into-medtronic-reveals-manipulated-studies-close-financial-ties-with-researchers)
- Shaffer, D., Scott, M., Wilcox, H., Maslow, C., Hicks, R., Lucas, C.P., Garfinkel, R., Greenwald, S. (2004), The Columbia Suicide Screen: validity and reliability of a screen for youth suicide and depression.



- Journal of the American Academy of Child and Adolescent Psychiatry*, 43, 71–79.
- Shapiro, A.K., Shapiro E. (1997), *The Powerful Placebo: From Ancient Priest to Modern Physician*. Baltimore: The Johns Hopkins University Press.
- Sherman, M., Burak, K., Maroun, J., Metrakos, P., Knox, J.J., Myers, R.P., Guindi, M., Porter, G., Kachura, J.R., Rasuli, P., Gill, S., Ghali, P., Chaudhury, P., Siddiqui, J., Valenti, D., Weiss, A., Wong. (2012), Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. *Current Oncology*, 18 (5), 228–240.
- Shoaf, T.L. (2004), Pediatric Psychopharmacology for the major psychiatric disorders found in the residential treatment setting. *Journal of Child and Adolescent Psychiatric Clinics of North America*. 13, 327–345.
- Simmons, G.H. (1907), The commercial domination of therapeutics and the movement for reform. *Journal of the American Medical Association*, XLVIII (20), 1645–1653.
- Singer, N. (2009), Medical papers by ghostwriters pushed therapy, *New York Times*, 5 August.
- Sismondo, S. (2007), Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? *PLoS Medicine*, 4(9), e286.
- Sismondo, S. (2009a), Ghosts in the machine: Publication planning in the medical sciences. *Social Studies of Science*, 39, 171–198.
- Sismondo, S. (2009b), Ghosts in the machine: Reply to McHenry. *Social Studies of Science*, 39/6, 949–952.
- Sismondo, S. (2018), *Ghost-managed medicine: Big pharma's invisible hands*. Manchester: Mattering Press.
- Sismondo, S., Doucet, M. (2010), Publication ethics and the ghost management of medical publication. *Bioethics*, 24/6, 273–283.
- Smith, R. (2005), Medical journals are an extension of the marketing arm of pharmaceutical companies. *PLoS Medicine*, 2(5), e138.
- Smith, R. (2006a), Lapses at the New England Journal of Medicine. *Journal of the Royal Society of Medicine*, 99, 1–3.
- Smith, R. (2006b), *The Trouble with Medical Journals*. London: The Royal Society of Medicine Press.
- SmithKline Beecham (1992), Adolescent Unipolar Major Depression: Multisite Psychopharmacology Study. Draft of 5 Dec. [www.healthyskepticism.org/documents/documents/19921205KellerProposal.pdf](http://www.healthyskepticism.org/documents/documents/19921205KellerProposal.pdf)
- SmithKline Beecham. (1993), A Multi-center, Double-blind, Placebo Controlled Study of Paroxetine and Imipramine in Adolescents



- with Unipolar Major Depression 1993/Amended 1996. [www.healthyskepticism.org/documents/Protocol329.pdf](http://www.healthyskepticism.org/documents/Protocol329.pdf)
- SmithKline Beecham (1998a), Paxil Business Plan Guide. [abcnews.go.com/images/Primetime/paxil\\_bpg.pdf](http://abcnews.go.com/images/Primetime/paxil_bpg.pdf)
- SmithKline Beecham (1998b), Study 329 Proposal for a Journal Article. [www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/19980403STIContract.pdf](http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/19980403STIContract.pdf)
- SmithKline Beecham (1998c), A Multi-center, Double-blind, Placebo Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression—Acute Phase. Final Clinical Report. SB Document Number: BRL-029060/RSD-100TW9/1/CPMS-329. 24 November. [www.gsk.com/media/paroxetine/depression\\_329\\_full.pdf](http://www.gsk.com/media/paroxetine/depression_329_full.pdf)
- SmithKline Beecham (1998d), Draft I. 18 Dec. [www.healthyskepticism.org/documents/documents/DraftI.pdf](http://www.healthyskepticism.org/documents/documents/DraftI.pdf)
- SmithKline Beecham (1998e), SmithKline Beecham, Seroxat/Paxil adolescent depression position piece on the Phase III clinical studies, October 1998. [www.healthyskepticism.org/documents/documents/19981014PositionPiece.pdf](http://www.healthyskepticism.org/documents/documents/19981014PositionPiece.pdf)
- SmithKline Beecham (1998f), Laden, S., Romankiewicz, R. Adolescent Depression. Study 329. Proposal for a Journal Article. 03/04/1998, [www.healthyskepticism.org/documents/documents/19980403STIContract.pdf](http://www.healthyskepticism.org/documents/documents/19980403STIContract.pdf)
- SmithKline Beecham (1999a), Nulli Secundus Neuroscience Division. [www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/NulliSecundus\\_000.pdf](http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/NulliSecundus_000.pdf)
- SmithKline Beecham (1999b), Oakes to McCafferty, 05/03/1999. [www.healthyskepticism.org/documents/documents/990305OakestoMcC.pdf](http://www.healthyskepticism.org/documents/documents/990305OakestoMcC.pdf)
- SmithKline Beecham (1999c), McCafferty to Laden. [www.healthyskepticism.org/documents/documents/19990719McCaffertytoLaden.pdf](http://www.healthyskepticism.org/documents/documents/19990719McCaffertytoLaden.pdf)
- SmithKline Beecham (1999d), Keller to Laden, 02/11/1999. [www.healthyskepticism.org/documents/documents/19990211KellertoLaden\\_000.pdf](http://www.healthyskepticism.org/documents/documents/19990211KellertoLaden_000.pdf)
- SmithKline Beecham (1999e), The hidden diagnosis: training-the-trainer sessions to be held. [www.industrydocumentslibrary.ucsf.edu/drug/docs/ghgw0217](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/ghgw0217)
- SmithKline Beecham (1999f), Comments from 3 JAMA Reviewers. [www.healthyskepticism.org/documents/documents/19991022JAMAreviews.pdf](http://www.healthyskepticism.org/documents/documents/19991022JAMAreviews.pdf)
- SmithKline Beecham (1999g), Klein to B. Ryan, 04/15/1999. [www.healthyskepticism.org/documents/documents/19990415KleintoBRyan.pdf](http://www.healthyskepticism.org/documents/documents/19990415KleintoBRyan.pdf)



- SmithKline Beecham (1999h), Clarke to Ryan and Strober, 03/30/1999. [www.healthyskepticism.org/documents/documents/19990330ClarketoRyan.pdf](http://www.healthyskepticism.org/documents/documents/19990330ClarketoRyan.pdf)
- SmithKline Beecham (1999i), Draft Submitted to JAMA, 7/30/1999. [www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/19990726JAMAsubmission.pdf](http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/19990726JAMAsubmission.pdf)
- SmithKline Beecham (2000a), Psychnet: Paxil Clinicians Speaker Council, Consultant Resource Manual. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=xhgw0217](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=xhgw0217)
- SmithKline Beecham (2000b), PsychNet Fall 2000 Paxil Clinicians Speaker Council: A Slide Lecture Kit. [www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=fqfw0217](http://www.industrydocumentslibrary.ucsf.edu/drug/docs/#id=fqfw0217)
- SmithKline Beecham (2000c), Scientific Therapeutics Information Release Form 11/06/2000. [www.healthyskepticism.org/documents/documents/STIRelease.pdf](http://www.healthyskepticism.org/documents/documents/STIRelease.pdf). Last accessed March 2008
- SmithKline Beecham (2000d), Laden to McCafferty, 04/26/2000. [www.healthyskepticism.org/documents/documents/20000426LadentoMcCafferty.pdf](http://www.healthyskepticism.org/documents/documents/20000426LadentoMcCafferty.pdf).
- SmithKline Beecham (2000e), Response to JAACAP Reviewers, 3 November 2000. [www.healthyskepticism.org/documents/documents/responsetoJAACAPReviews.pdf](http://www.healthyskepticism.org/documents/documents/responsetoJAACAPReviews.pdf)
- SmithKline Beecham (2001a), Memo from Hawkins to all sales representatives selling paxil. [www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/20010816Hawkinstoreps.pdf](http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/20010816Hawkinstoreps.pdf)
- SmithKline Beecham (2001b), Med Query Letter, 11 Sep. [www.healthyskepticism.org/documents/documents/2001MedQuery.pdf](http://www.healthyskepticism.org/documents/documents/2001MedQuery.pdf)
- SmithKline Beecham (2001c), White to Hood, 03/05/2001. [www.healthyskepticism.org/documents/documents/20010305WhitetoHood.pdf](http://www.healthyskepticism.org/documents/documents/20010305WhitetoHood.pdf)
- SmithKline Beecham (2001d), Response to Queries from Mina Dulcan, 01/05/2001. [www.healthyskepticism.org/documents/documents/ResponsestoDulcan.pdf](http://www.healthyskepticism.org/documents/documents/ResponsestoDulcan.pdf)
- SmithKline Beecham (2001e), Pretre to Keller, 02/06/2001. [www.healthyskepticism.org/documents/documents/20010206PretretoKeller.pdf](http://www.healthyskepticism.org/documents/documents/20010206PretretoKeller.pdf)
- Sokal, A.D. (1996), Transgressing the Boundaries: Towards a Transformative Hermeneutics of Quantum Gravity. *Social Text*, 46/47, 217–252.
- Spielmans, G.I., Parry, P.I. (2010), From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. *Journal of Bioethical Inquiry*, 7, 13–29.



- Steele, M.M., Doey, T. (2007), Suicidal behaviour in children and adolescents, Part 2: Treatment and Prevention. *Canadian Journal of Psychiatry*. 2007. 52, 35S–45S.
- Stegenga, J. (2018), *Medical Nihilism*. Oxford: Oxford University Press.
- Steiner, M., Pearlstein, T., Cohen, L.S., Endicott, J., Kornstein, S.G., Roberts, C., Roberts, D.L., Yonkers, K. (2006), Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: The role of SSRIs. *Journal of Women's Health*, 15(1), 57–69.
- Steinman, M.A., Bero, L.A., Chren, M.M., Landefeld, C.S. (2006), Narrative review: The promotion of Gabapentin: An analysis of internal industry documents. *Annals of Internal Medicine*, 145, 284–293.
- Sweeney, H. (2005), Letter to the editor. Pharma PR or medical education? *Hasting Center Report*, 35 (2), 4.
- Szasz, T. (1970), *Ideology and Insanity: Essays on the Psychiatric Dehumanization of Man*. New York: Anchor Books.
- Teicher, M.H., Glod, C., Cole, J.O. (1990), Suicidal preoccupation during fluoxetine treatment. *American Journal of Psychiatry*, 147, 1380–1381.
- Tierney, W.M., Gerrity, M.S. (2005), Scientific discourse, corporate ghostwriting, journal policy, and public trust. *Journal of General Internal Medicine*, 20(6), 550–551.
- Thomas, C., Conrad, P., Casler, R., Goodman, E. (2006), Trends in the use of psychotropic medications among adolescents, 1994–2001. *Psychiatric Services* 57, 63–69.
- Timimi, S. (2017), Starting young: Children cultured into becoming psychopharmaceutical consumers—the example of childhood depression. Edited by James Davies. *The Sedated Society: The Causes and Harms of Our Psychiatric Drug Epidemic*. Cham: Palgrave Macmillan.
- Topol, E.J. (2004), Failing the public health—Rofecoxib, Merck, and the FDA. *New England Journal of Medicine*, 351, 1707–1709.
- US Preventive Services Task Force. (2009), Screening and treatment for major depressive disorder for children and adolescents: US Preventive Services Task Force recommendations statement. *Pediatrics*, 123, 1223–1228.
- Van Zee, A. (2009), The promotion and marketing of Oxycontin: Commercial triumph, public health tragedy. *American Journal of Public Health*, 99(2), 221–227.
- Vedula, S.S., Bero, L., Scherer, R.W., Dickersin, K. (2009), Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *New England Journal of Medicine*, 361, 1963–1971.
- Ventola, C.L. (2011), Direct-to-consumer pharmaceutical advertising: Therapeutic or toxic? *P & T: A Peer-Reviewed Journal for Formulary Management*, 36 (10), 669–684.



- von Knorring, A.L., Olsson, G.I., Thomsen, P.H., Lemming, O.M., Hulten, A. (2006), A randomized, double-blind, placebo-controlled study of citalopram in adolescents with depression. *Journal of Clinical Psychopharmacology*, 26(3), 311–315.
- Wager, E., Field, E.A., Grossman, L. (2003). Good publication practice for pharmaceutical companies. *Current Medical Research & Opinion*, 19, 149–154.
- Wagner, K.D. (2018), President's address: Depression awareness and screening in children and adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry*, 57(1), 6–7.
- Wagner, K.D., Robb, A.S., Findling, R.L., Jin, J., Gutierrez, M.M., Heydorn, W.E. (2004), A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. *American Journal of Psychiatry*, 161 (6), 1079–1083.
- Wagner, K.D., Robb, A.S., Findling, R.L., Jin, J., (2005), Dr Wagner and colleagues reply. *American Journal of Psychiatry*, 162(4), 819.
- Wagner, W., Steinzor, R. (2006), *Rescuing Science from Politics*. Cambridge: Cambridge University Press.
- Walkup, J.T., (2017), Antidepressant efficacy for depression in children and adolescents: Industry- and NIMH-funded studies. *American Journal of Psychiatry*, 174 (5), 430–437.
- Washburn, J. (2005), *University, Inc.: The Corporate Corruption of Higher Education*. New York: Basic Books.
- Waters, R. (2012), GlaxoSmithKline's \$3 Billion Hit: Deterrent or Business Expense? *Forbes*, 12 July 2012.
- Whitaker, R., Cosgrove, L. (2015), *Psychiatry Under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform*. New York: Palgrave Macmillan.
- Whittington, C.J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., Boddington, E. (2004), Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. *Lancet*, 363, 1341–1345.
- Wilson, D. (2010), Drug maker wrote book under 2 doctors' names, documents say. *New York Times*, 30 November, B3.
- Wilson, J.M.G., Jungner, G. (1968), *Principles and Practice of Screening for Disease*. Geneva: World Health Organization.
- World Health Organization. (2019), *Model List of Essential Medicines, 21st List*. Geneva: World Health Organization.